Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

Item

http://www.wikidata.org/entity/Q50107451

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

@en

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

@nl

type

Item

label

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

@en

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

@nl

prefLabel

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

@en

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

@nl

P1476

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

@en

P2093

Anders Sönnerborg

http://www.w3.org/2001/XMLSchema#string

Clas F R Källander

http://www.w3.org/2001/XMLSchema#string

Eva Agneskog

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.

Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma.

From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.

Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

P304

703-708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMV.23507

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Piotr Nowak

P577

2013-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23364785

http://www.w3.org/2001/XMLSchema#string